💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

BioPharmX acne candidate successful in mid-stage study; shares ahead 8% premarket

Published 06/01/2017, 08:49 AM
© Reuters.  BioPharmX acne candidate successful in mid-stage study; shares ahead 8% premarket
TMBRQ
-
  • Nano cap BioPharmX (NYSEMKT:BPMX) is up 8% premarket on higher-than-normal volume in response to its announcement of positive results from a Phase 2b clinical trial assessing the 2% formulation of BPX-01 for the treatment of acne vulgaris. The data showed treatment with BPX-01 reduced the number of inflammatory lesions by 59% compared to 44% for vehicle (placebo) at week 12, a statistically significant result. The were no serious drug-related adverse events observed.
  • The data will be presented today at the "State of Acne" symposium in NYC.
  • BPX-01 is a fully solubilized, non-oily topical minocycline gel. The formulation delivers the antibiotic directly to the source of acne while avoiding systemic exposure.
  • Now read: InsiderInsights.com Daily Round Up 5/1/17: CVA, APO, IFF, SPN, JFC, GLO


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.